RetroClipArt / Shutterstock.com
There is no uniform interpretation of the scope of the Bolar exemption in Europe, but a CJEU opinion harmonising the issue may be on the way, says Rafal Witek.
In recent months, we’ve had the opportunity to analyse the final decisions of the courts in Poland and Germany on the Astellas v Polpharma case interpreting the range of the Bolar exemption in Europe (for earlier details of the case click here).
In the case, Polish company Zakłady Farmaceutyczne Polpharma SA (Polpharma) produced an active pharmaceutical ingredient (API) which it offered it to other companies, and in particular to a German company Hexal AG, claiming the API was being offered only to allow them to carry out whatever activities were necessary to obtain marketing approval (MA) for a generic product.
The plaintiff, Astellas Pharma Inc, sued Polpharma for infringing its German and Polish patents protecting the API offered by Polpharma. Polpharma argued that its activities did not infringe Astellas’ patent because they were covered by the Bolar exemption defined in both Polish law (Article 69.1.[iv] IPL) and German law (§11 Nr. 2b PatG).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Bolar, CJEU, patented substances, patent infringement